This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

This study has been withdrawn prior to enrollment.
(Insufficient Enrollment)
Information provided by:
Bristol-Myers Squibb Identifier:
First received: May 9, 2006
Last updated: February 16, 2016
Last verified: April 2011
The purpose of this study is to find out whether adding a new drug, dasatinib, to imatinib is safe, and whether the combination of the two drugs will help decrease the number of cells that contain the Philadelphia chromosome.

Condition Intervention Phase
Myeloid Leukemia, Chronic, Chronic-Phase Drug: Dasatinib in combination with imatinib Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Study of the Combination of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • To determine the maximum tolerated dose (MTD) and recommended dose of dasatinib when combined with imatinib in chronic phase CML patients.

Secondary Outcome Measures:
  • assess safety and tolerability of dasatinib and imatinib administered in combination throughout study
  • identify dose limiting toxicities
  • characterize plasma pharmacokinetics of dasatinib and imatinib in month 1
  • measure major molecular response rate
  • measure the major cytogenetic response rate
  • characterize mutations in the BCR-ABL gene
  • evaluate progressive free survival and overall survival

Enrollment: 0
Study Start Date: August 2006
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • males and females, 18 or older
  • chronic phase Ph+ or BCR-ABL positive CML
  • current complete hematologic response to imatinib
  • lack of major molecular response
  • on imatinib for at least one year
  • on the same imatinib dose for at least 6 months
  • adequate hepatic and renal function

Exclusion Criteria:

  • History of accelerated or blast phase CML
  • Serious uncontrolled medical disorder or active infection
  • Significant cardiovascular disease or bleeding disorder
  • Concurrent use of medications at risk of causing Torsades de Pointe
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00324077

United States, California
Local Institution
Los Angeles, California, United States
Local Institution
San Francisco, California, United States
United States, New York
Local Institution
New York, New York, United States
Sponsors and Collaborators
Bristol-Myers Squibb
  More Information

Additional Information: Identifier: NCT00324077     History of Changes
Other Study ID Numbers: CA180-011
Study First Received: May 9, 2006
Last Updated: February 16, 2016

Keywords provided by Bristol-Myers Squibb:
Chronic phase chronic myelogenous leukemia (CML)

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic-Phase
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 22, 2017